Immunotherapy Demonstrates Long-Term Success In Treating Lymphoma Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).
Source: www.medicalnewstoday.comShire Reports Tolerability And Clinical Effects Results Of Daytrana(R) (methylphenidate Transdermal System) From Study In Adolescents With ADHD Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). In addition, data regarding the pharmacokinetic profile of Daytrana in children and adolescents was also presented.
Source: www.medicalnewstoday.comBayer HealthCare Presents Florbetaben Phase II Study Results At World Congress Of Neurology Bayer HealthCare presented results from a global Phase II study of florbetaben, its imaging agent in development for the detection of cerebral beta-Amyloid plaques, at the 19th World Congress of Neurology (WCN). The purpose of the Phase II study was to investigate the efficacy of florbetaben in differentiating between patients with a clinical diagnosis of probable Alzheimer's disease and Healthy Volunteers (HVs).
Source: www.medicalnewstoday.com
# posted by Network @ 11:46 PM
